October 2020 Special Edition
Volume 6, Issue 12.1
This supplement takes a look at new guidelines for the treatment of TTP, the latest FDA approvals for the treatment of red blood cell and iron disorders, and more.
Table of Contents
FDA Approvals
The Year in FDA Approvals
Here, we review recent therapies approved by the U.S. Food and Drug Administration for the treatment of red blood cell and iron disorders, including...
October 2020 Special Edition
New Rules of the Road in TTP Management
In July 2020, the International Society on Thrombosis and Haemostasis (ISTH) issued its first-ever guidelines for the treatment of thrombotic thrombocytopenic purpura (TTP), helping...
Questions and Controversies in Iron-Deficiency Anemia
Iron-deficiency is the most common nutritional deficiency in the world. It affects patients in both developed and developing countries and has been commonly recognized...
October 2020 Special Edition
Hydroxyurea Treatment Before Puberty Does Not Impair Future Sperm Quality in Boys With SCD
Childhood hydroxyurea (hydroxycarbamide) treatment does not impair future sperm parameters in boys with severe sickle cell disease (SCD), according to research published in Blood....
Tranexamic Acid for Gastrointestinal Bleeding: Time to HALT-IT?
Although tranexamic acid reduces the risks of surgical bleeding and bleeding-related death in patients with trauma, it does not reduce risk of death from...
Rivaroxaban and Standard Anticoagulants Safe, Reduce Clot Burden in Most Children With CVC-VTE
In most children with central venous catheter-related venous thromboembolism (CVC-VTE), treatment with rivaroxaban or other standard anticoagulants reduced clot burden, according to results from...
October 2020 Special Edition
Investigating Tyrosine Kinase Inhibitors for ITP
In two presentations presented at EHA25 Virtual, the 25th European Hematology Association Annual Congress, investigators shared updates on two kinase inhibitors for the treatment...
ADAMTS13 Activity Levels Predict iTTP Recurrence
A study presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress confirms the value of longitudinal quarterly assessment of ADAMTS13...
Studies Confirm Long-Term Benefit of Gene Therapy for Hemophilia A
In two studies presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress, gene therapies for hemophilia A demonstrated durable increases...
Is It Time for a Paradigm Shift for CAPS Treatment?
Newer treatment approaches that incorporate monoclonal antibodies reduce the mortality risk in patients with catastrophic antiphospholipid syndrome (CAPS), according to research presented at the...
